Former Aetna CEO Ron Williams weighs in on what changes could be ahead for the Affordable Care Act and consumers. » Read More
By: Dan Mangan
UnitedHealth denies allegations it gamed the nation's Medicare system for hundreds of millions of dollars. » Read More
By: Elizabeth Gurdus
The burdens of repealing and replacing Obamacare will fall on consumers, Mark Cuban tells CNBC. » Read More
By: Bertha Coombs
House Speaker Paul Ryan said they plan to introduce legislation as early as next Tuesday. » Read More
Here are how some food-related stocks are moving on news of an avian flu outbreak in Iowa.
The sheer volume and pace of biotech offerings are causing some to question whether the sector is nearing the end of its years of buoyancy.
Executives at J.P. Morgan's healthcare conference discuss the technologies they believe with change medicine as we know it.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Ariad CEO Harvey Berger, tells CNBC's Meg Tirrell commercially the company had a good year and provides insight into its new cancer drug, Iclusig.
Vertex CEO Dr. Jeffrey Leiden tells CNBC's Meg Tirrell about the company's new drug trials and focus areas in 2015.
Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.
Hans Bishop, Juno Therapeutics co-founder and CEO, discusses promising data for new cancer immunotherapy approaches.
David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.
Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.
Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.
Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.
Alex Gorsky, Johnson & Johnson chairman and CEO, discusses how the ACA and the recovery in the economy is impacting business.
Flemming Ornskov, Shire CEO, tells CNBC's Meg TIrrell it is the right time for the proposed acquisition of NPS Pharmaceuticals.
Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
Dr. David Schenkein, Agios CEO, explains a cancer's metabolism, and the company's priorities for 2015.
Bluebird Bio CEO Nick Leschly, provides insight to how gene therapy can work to treat blood disorders, and sickle cell anemia.
Brent Saunders, Actavis CEO, discusses the deal environment, the process of acquiring Allergan and the good that comes from activist investors.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
Get the best of CNBC in your inbox